Latest News for CZMWF
Carl Zeiss Meditec AG (CZMWY) Q1 2026 Earnings Call Transcript
Carl Zeiss Meditec is rated a 'Strong Buy' with higher share price target, reflecting significant undervaluation and robust fundamentals. The company achieved over €2.2B in revenue (+7.5% YoY), strong order backlog, and over 50% recurring revenue, enhancing earnings stability. Despite Chinese market headwinds and low yield (1.3%), the company's vertical integration, innovation, and market leadership support a…
Invesco Global Opportunities Fund outperformed most in consumer staples due to stock selection and in real estate due to an underweight allocation. Stock selection in consumer discretionary, IT and materials were the largest detractors from relative performance. An underweight in materials also detracted. Palantir Technologies' stock continued to trade well amid expectations for strong AI demand.
Carl Zeiss Meditec AG (CZMWY) Q4 2025 Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Discusses CEO Transition and Management Continuity Strategy Following Code of Conduct Investigation Transcript
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CZMWF.
Senate Trading
No Senate trades found for CZMWF.
U.S. House Trading
No House trades found for CZMWF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.